Patents by Inventor Veronique Barban

Veronique Barban has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dengue serotype 1 attenuated strain
    Patent number: 9169298
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: October 27, 2015
    Assignees: Centers for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • VACCINE COMPOSITIONS FOR PREVENTION AGAINST DENGUE VIRUS INFECTION
    Publication number: 20150265695
    Abstract: The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.
    Type: Application
    Filed: July 24, 2013
    Publication date: September 24, 2015
    Inventors: Jiansheng Yao, Yves Girerd-Chambaz, Isabelle Legastelois, Nathalie Mantel, Véronique Barban, Jean Lang, Bruno Guy
  • DENGUE SEROTYPE 2 ATTENUATED STRAIN
    Publication number: 20150031857
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Application
    Filed: August 4, 2014
    Publication date: January 29, 2015
    Inventors: Richard KINNEY, Claire Y.H. Kinney, Veronique Barban, Jean Lang, Bruno Guy
  • Dengue serotype 2 attenuated strain
    Patent number: 8795688
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: August 5, 2014
    Assignees: Sanofi Pasteur, Centers for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • DENGUE SEROTYPE 2 ATTENUATED STRAIN
    Publication number: 20120083585
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Application
    Filed: October 25, 2011
    Publication date: April 5, 2012
    Inventors: Richard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • DENGUE SEROTYPE 1 ATTENUATED STRAIN
    Publication number: 20120083584
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Application
    Filed: October 25, 2011
    Publication date: April 5, 2012
    Inventors: Richard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Dengue serotype 2 attenuated strain
    Patent number: 8067566
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: November 29, 2011
    Assignees: Sanofi Pasteur, Centers for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Dengue serotype 1 attenuated strain
    Patent number: 8067565
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: November 29, 2011
    Assignees: Sanofi Pasteur, Centers For Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Method of Immunization Against the 4 Dengue Serotypes
    Publication number: 20100270202
    Abstract: The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising (a) a first series of administrations (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, and (b) a second series of administrations of doses (i) and (ii), in which the doses (i) and (ii) are administered simultaneously at separate anatomical sites, and in which the second series (b) is implemented at least 30 days to at most 12 months after the first series (a).
    Type: Application
    Filed: March 5, 2010
    Publication date: October 28, 2010
    Applicant: SANOFI PASTEUR SA
    Inventors: Bruno Guy, Rémi Forrat, Jean Lang, Véronique Barban
  • Method of Immunization Against the 4 Serotypes of Dengue Fever
    Publication number: 20100239612
    Abstract: The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising: (a) the administration of a monovalent vaccine comprising a vaccinal virus of a first serotype of dengue fever, and (b) the administration of a tetravalent vaccine comprising vaccinal viruses of the four serotypes of dengue fever, in which administration (b) is made between at least 30 days and not more than 12 months following the first administration (a).
    Type: Application
    Filed: March 5, 2010
    Publication date: September 23, 2010
    Applicant: SANOFI PASTEUR SA
    Inventors: Bruno Guy, Veronique Barban, Remi Forrat, Jean Lang
  • Method of Immunization Against the 4 Dengue Serotypes
    Publication number: 20100221285
    Abstract: The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, in which the vaccinal dengue viruses (ii) are administered at least 30 days and at most 1 year after administration of the vaccinal viruses (i).
    Type: Application
    Filed: March 5, 2010
    Publication date: September 2, 2010
    Applicant: SANOFI PASTEUR SA
    Inventors: Véronique Barban, Rémi Forrat, Bruno Guy, Jean Lang
  • DENGUE SEROTYPE 2 ATTENUATED STRAIN
    Publication number: 20100174057
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Application
    Filed: December 8, 2009
    Publication date: July 8, 2010
    Inventors: Richard Kinney, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • DENGUE SEROTYPE 1 ATTENUATED STRAIN
    Publication number: 20100137571
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Application
    Filed: December 8, 2009
    Publication date: June 3, 2010
    Inventors: RICHARD KINNEY, CLAIRE Y.H. KINNEY, VÉRONIQUE BARBAN, JEAN Lang, BRUNO GUY
  • Method of immunization against the 4 serotypes of dengue fever
    Patent number: 7718359
    Abstract: The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising: (a) the administration of a monovalent vaccine comprising a vaccinal virus of a first serotype of dengue fever, and (b) the administration of a tetravalent vaccine comprising vaccinal viruses of the four serotypes of dengue fever, in which administration (b) is made between at least 30 days and not more than 12 months following the first administration (a).
    Type: Grant
    Filed: November 21, 2007
    Date of Patent: May 18, 2010
    Assignee: Sanofi Pasteur SA
    Inventors: Bruno Guy, Veronique Barban, Remi Forrat, Jean Lang
  • Method of immunization against the 4 dengue serotypes
    Patent number: 7718357
    Abstract: The invention relates to a method for inducing a homologous protection against the 4 dengue serotypes in a patient, comprising the sequential administration, to said patient, (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, in which the vaccinal dengue viruses (ii) are administered at least 30 days and at most 1 year after administration of the vaccinal viruses (i).
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: May 18, 2010
    Assignee: Sanofi Pasteur SA
    Inventors: Bruno Guy, Véronique Barban, Rémi Forrat, Jean Lang
  • Method of immunization against the 4 dengue serotypes
    Patent number: 7718358
    Abstract: The invention relates to a method for inducing a protection against the 4 dengue serotypes in a patient, comprising (a) a first series of administrations (i) of a dose of a vaccinal dengue virus of a first serotype and of a dose of a vaccinal dengue virus of a second serotype, and (ii) of a dose of a vaccinal dengue virus of a third serotype and of a dose of a vaccinal dengue virus of a fourth serotype, and (b) a second series of administrations of doses (i) and (ii), in which the doses (i) and (ii) are administered simultaneously at separate anatomical sites, and in which the second series (b) is implemented at least 30 days to at most 12 months after the first series (a).
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: May 18, 2010
    Assignee: Sanofi Pasteur SA
    Inventors: Bruno Guy, Remi Forrat, Jean Lang, Veronique Barban
  • Dengue serotype 2 attenuated strain
    Patent number: 7641908
    Abstract: The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells. The invention further relates to a vaccine composition which comprises a VDV2 strain.
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: January 5, 2010
    Assignees: Sanofi Pasteur, Center for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Dengue serotype 1 attenuated strain
    Patent number: 7641907
    Abstract: The invention relates to live attenuated VDV1 (VERO-Derived Dengue serotype 1 virus) strains which have been derived from the wild-type dengue-1 strain 16007 by passaging on PDK and sanitization on Vero cells. The invention further relates to a vaccine composition which comprises a VDV1 strain.
    Type: Grant
    Filed: June 9, 2006
    Date of Patent: January 5, 2010
    Assignees: Sanofi Pasteur, Center for Disease Control and Prevention
    Inventors: Richard Kinney, Claire Y. H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
  • Method of Immunization Against the 4 Serotypes of Dengue Fever
    Publication number: 20080131460
    Abstract: The invention relates to a method for inducing protection against the 4 serotypes of dengue fever in a patient, comprising: (a) the administration of a monovalent vaccine comprising a vaccinal virus of a first serotype of dengue fever, and (b) the administration of a tetravalent vaccine comprising vaccinal viruses of the four serotypes of dengue fever, in which administration (b) is made between at least 30 days and not more than 12 months following the first administration (a).
    Type: Application
    Filed: November 21, 2007
    Publication date: June 5, 2008
    Applicant: SANOFI PASTEUR SA
    Inventors: Bruno GUY, Veronique BARBAN, Remi FORRAT, Jean LANG
  • Live Attenuated Dengue 3 Virus Strains
    Publication number: 20080107685
    Abstract: The invention relates to live attenuated dengue serotype 3 virus strains which have been produced by site directed mutagenesis of an attenuated dengue 3 strain.
    Type: Application
    Filed: June 1, 2007
    Publication date: May 8, 2008
    Applicant: SANOFI PASTEUR
    Inventors: Veronique Barban, Marie-Jose Quentin-Millet, Regis Sodoyer